Health activists seek revision of India’s essential medicines list to ensure price cap, availability

2026-07-05 · 4 min

UPSC CSE Context Why in News: Civil society demands revision of India's National List of Essential Medicines NLEM after four year gap, citing WHO updates and missing cancer drugs. Syllabus Connection: GS Paper 2: Issues relating to health, government policies and interventions; GS Paper 3: Pricing of pharmaceuticals. Exam Relevance: Highlights policy lag in essential medicines, price regulation, and right to health; relevant for health governance and social justice questions. Core Issue NLEM not updated since 2022; WHO list revised twice; missing cancer and biologic drugs. Key Development: Working Group on Access to Medicines and Treatments writes to government for urgent NLEM revision. Stakeholders: Ministry of Health and Family Welfare National Pharmaceutical Pricing Authority NPPA Patients especially cancer and diabetes Static Knowledge High Value Background: NLEM is a list of essential medicines used to ensure availability and affordability; inclusion triggers price ceiling by NPPA

## UPSC CSE Context **Why in News:** Civil society demands revision of India's National List of Essential Medicines (NLEM) after four-year gap, citing WHO updates and missing cancer drugs. **Syllabus Connection:** GS Paper 2: Issues relating to health, government policies and interventions; GS Paper 3: Pricing of pharmaceuticals. **Exam Relevance:** Highlights policy lag in essential medicines, price regulation, and right to health; relevant for health governance and social justice questions. ## Core Issue NLEM not updated since 2022; WHO list revised twice; missing cancer and biologic drugs. **Key Development:** Working Group on Access to Medicines and Treatments writes to government for urgent NLEM revision. **Stakeholders:** - Ministry of Health and Family Welfare - National Pharmaceutical Pricing Authority (NPPA) - Patients (especially cancer and diabetes) ## Static Knowledge **High-Value Background:** - NLEM is a list of essential medicines used to ensure availability and affordability; inclusion triggers price ceiling by NPPA. - WHO Model List of Essential Medicines serves as global benchmark, updated every two years. **Exam Linkage:** - Useful for questions on health policy, drug pricing, and right to health under Article 21. **Concepts in Context:** - Essential medicines: drugs that satisfy priority healthcare needs, selected based on disease prevalence, efficacy, safety, and cost-effectiveness. - Price ceiling: maximum price set by NPPA for essential medicines to ensure affordability. ## Dynamic Analysis ### Governance - Four-year delay in NLEM revision indicates bureaucratic inertia and lack of periodic review mechanism. - Absence of transparent, time-bound process for updating list undermines public health preparedness. - Conflict of interest concerns if pharmaceutical industry influences list composition. ### Health - Missing cancer drugs and monoclonal antibodies from NLEM denies patients access to modern treatments. - Diabetes and cancer patients face higher out-of-pocket expenditure due to absence of price caps. - India's list includes locally relevant drugs (e.g., TB) but gaps in oncology reflect global standard-of-care lag. ### Constitutional/Legal - Price control through NLEM is a state obligation to ensure affordable healthcare; non-update weakens this commitment. - Constitutional duty to protect life includes access to essential medicines; delay has human rights implications. ### Economy - Price ceiling on essential medicines reduces out-of-pocket spending, crucial for low-income households. - Non-inclusion of new drugs keeps prices high in private market, increasing financial burden on patients. - Timely revision can stimulate generic production and competition, lowering costs. ## Mains Value Addition **Arguments:** - Periodic revision of NLEM is essential to align with evolving disease burden and medical advancements. - Price regulation through NLEM is a key tool for achieving Universal Health Coverage. - Delay disproportionately affects vulnerable populations with chronic diseases like cancer and diabetes. - India's list need not mirror WHO list but must address critical gaps in life-threatening conditions. **Examples:** - 17 active cancer-treating agents and 4 supportive cancer-care medicines on WHO list but missing from NLEM. - Nine monoclonal antibodies absent from NLEM despite being standard in modern cancer treatment. **Data Points:** - NLEM last updated on September 13, 2022. - WHO list expanded to 523 medicines in 2025 from 384 in India's NLEM. **Counterpoints:** - Some deviation from WHO list is legitimate due to India's specific disease burden and cost considerations. - Frequent revisions may disrupt supply chains and increase administrative burden. - Price caps could reduce profitability, potentially discouraging production of essential medicines. ## Way Forward - Establish a statutory timeline for mandatory NLEM revision every two years. - Ensure transparent, conflict-of-interest-free process involving clinicians, public health experts, and civil society. - Prioritize inclusion of missing cancer drugs and biologics based on disease burden and global evidence. - Strengthen NPPA's capacity to enforce price ceilings promptly after NLEM update. - Link NLEM revision with procurement and supply chain planning to ensure availability in public hospitals.

Source: National News